for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lennox International Inc.

LII

Latest Trade

284.03USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

163.40

 - 

297.00

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
284.03
Open
--
Volume
--
3M AVG Volume
5.08
Today's High
--
Today's Low
--
52 Week High
297.00
52 Week Low
163.40
Shares Out (MIL)
38.29
Market Cap (MIL)
10,651.81
Forward P/E
--
Dividend (Yield %)
1.11

Next Event

Q4 2020 Lennox International Inc Earnings Release

Latest Developments

More

Lennox International Raises 2020 Guidance

Lennox International Announces Pricing Of $600 Mln Senior Notes Offering

Lennox International Reports Q2 Adjusted Earnings Per Share $2.97 From Continuing Operations

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lennox International Inc.

Lennox International Inc. is a provider of climate control solutions. The Company designs, manufactures and markets a range of products for the heating, ventilation, air conditioning and refrigeration (HVACR) markets. It operates through three segments: Residential Heating & Cooling; Commercial Heating & Cooling, and Refrigeration. It manufactures and markets a range of furnaces, air conditioners, heat pumps, packaged heating and cooling systems, equipment and accessories to manage indoor air quality, comfort control products, replacement parts and supplies and related products for both the residential replacement and new construction markets in North America. It manufactures and sells unitary heating and cooling equipment used in light commercial applications, such as low-rise office buildings, restaurants, retail centers, churches and schools. It manufactures and markets equipment for the global commercial refrigeration markets under the Heatcraft Worldwide Refrigeration name.

Industry

Misc. Capital Goods

Contact Info

2140 Lake Park Blvd

RICHARDSON, TX

75080

United States

+1.972.4975000

https://www.lennoxinternational.com/

Executive Leadership

Todd M. Bluedorn

Chairman of the Board, Chief Executive Officer

Joseph W. Reitmeier

Chief Financial Officer, Executive Vice President

Daniel M. Sessa

Chief Human Resource Officer, Executive Vice President

Prakash Bedapudi

Chief Technology Officer, Executive Vice President

John D. Torres

Chief Legal Officer, Executive Vice President, Secretary

Key Stats

3.11 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

3.8K

2018

3.8K

2019

3.8K

2020(E)

3.5K
EPS (USD)

2017

7.920

2018

9.420

2019

11.190

2020(E)

8.836
Price To Earnings (TTM)
30.05
Price To Sales (TTM)
2.95
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
24.66
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
30.20
Return on Equity (TTM)
17.09

Latest News

Latest News

European panel okays GW Pharma cannabis drug for epilepsy

GW Pharmaceuticals' marijuana-based treatment Epidyolex has won a positive recommendation for marketing approval from a European Medicines Agency (EMA) panel on Friday for use as an additional treatment for two types of seizures.

BRIEF-Lennox International Increases Dividend 25 Percent

* SETS QUARTERLY CASH DIVIDEND OF $0.64PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Lennox International Reports Q1 Adjusted Earnings Per Share $1.13 From Continuing Operations

* LENNOX INTERNATIONAL REPORTS RECORD FIRST-QUARTER REVENUE AND PROFIT

BRIEF-Lennox International Says CEO's 2017 Compensation Was $11.45 Mln

* LENNOX INTERNATIONAL INC SAYS CEO TODD M. BLUEDORN'S 2017 TOTAL COMPENSATION WAS $11.45 MILLION VERSUS $10 MILLION IN 2016 – SEC FILING Source: (https://bit.ly/2GUhs6F) Further company coverage:

BRIEF-Lennox International Q4 EPS $1.02 From Continuing Operations

* LENNOX INTERNATIONAL REPORTS RECORD FOURTH QUARTER MARGIN AND PROFIT TO CAP RECORD YEAR AND RAISES 2018 EPS GUIDANCE FOR U.S. TAX LEGISLATION

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME

BRIEF-Lennox International Sees Fy18 Revenue Up 3 To 7 Percent

* REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $7.75 TO $8.05 FROM CONTINUING OPERATIONS

BRIEF-Lennox International says Lpac, co entered into amendment to amended, restated receivables purchase agreement initially dated Nov 18, 2011

* Lennox International - as of Nov 13, Lennox, Lpac, co entered into amendment to amended, restated receivables purchase agreement initially dated nov 18, 2011

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up